Oncology Consultants

Houston, Texas 777024

14 studies enrolling now · 62 studies all time

What they study most

1st Line NSCLC, Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adenoma, Adult Solid Tumor, Advanced Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Advanced or Metastatic Solid Tumors, Advanced/Metastatic Solid Tumors, B-cell Malignancy, Basal Cell Carcinoma

Studies at this site

• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — Recruiting now
• SLV-154 Treatment of Advanced Cancers — Recruiting now
• Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers — Recruiting now
• Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors — Recruiting now
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) — Recruiting now
• An External Control Arm Study in Non-Small Cell Lung Cancer — Recruiting now
• A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Recruiting now
• Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain — Recruiting now
• A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma — Recruiting now
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer — Recruiting now
• Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma — Recruiting now
• A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer — Recruiting now
• A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors — Recruiting now
• AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma — Recruiting now
• BostonGene and Exigent Genomic INsight Study — Recruiting now
• Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy — Stopped early
• A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer — Stopped early
• A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment — Completed
• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Running, not enrolling
• Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) — Running, not enrolling
• Prevention of Colorectal Cancer Through Multiomics Blood Testing — Completed
• Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC — Completed
• Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors — Stopped early
• Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) — Running, not enrolling
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma — Running, not enrolling
• The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening — Completed
• Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer — Completed
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC — Running, not enrolling
• Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer — Stopped early
• Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling — Completed
• Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation — APPROVED_FOR_MARKETING
• Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) — Stopped early
• A Study of NDI 1150-101 in Patients With Solid Tumors — Running, not enrolling
• Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 — Stopped early
• Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) — Running, not enrolling
• Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) — Status unconfirmed
• Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer — Stopped early
• A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma — Completed
• Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine — Completed
• A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations — Status unconfirmed
• MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC — Stopped early
• Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy — Completed
• Study of HL-085 in Patients With Advanced Solid Tumor Tumors — Completed
• KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC — Stopped early
• Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) — Stopped early
• SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) — Completed
• A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation — Status unconfirmed
• Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer — Stopped early